CVRx, Inc. (CVRX) recently announced the availability of additional data supporting the long-term benefits of Barostim. This includes the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight the long-term sustained benefits of Barostim in heart failure (HF) patients with reduced ejection fraction. It should be noted that BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April 2016 to develop scien ...